Related Experiment Video
Updated: Sep 10, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Artificial Intelligence in Gestational Diabetes Care: A Systematic Review
Rawan AlSaad1, Ali Elhenidy2, Aliya Tabassum3
1AI Center for Precision Health, Weill Cornell Medicine-Qatar, Doha, Qatar.
Background:
Artificial intelligence (AI) has emerged as a transformative tool for advancing gestational diabetes mellitus (GDM) care, offering dynamic, data-driven methods for early detection, management, and personalized intervention.
Objective:
This systematic review aims to comprehensively explore and synthesize the use of AI models in GDM care, including screening, diagnosis, management, and prediction of maternal and neonatal outcomes. Specifically, we examine (1) study designs and population characteristics; (2) the use of AI across different aspects of GDM care; (3) types of input data used for AI modeling; and (4) AI model types, validation strategies, and performance metrics.
Methods:
A systematic search was conducted across six electronic databases, identifying 126 eligible studies published up to February 2025. Data extraction and quality appraisal were independently conducted by six reviewers, using a modified version of the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool for risk of bias assessment.
Results:
Among 126 studies, 75% employed retrospective designs, with sample sizes ranging from 17 to over 100 000 participants. Most AI applications (85%) focused on early GDM prediction, while fewer addressed management, outcomes, or monitoring. Classical machine learning dominated (84%), with logistic regression and random forest frequently used. Internal validation was common (68%), but external validation was rare (6%). Our risk of bias appraisal indicated an overall moderate-to-good methodological quality, with notable deficiencies in analysis reporting.
Conclusions:
AI demonstrates strong potential to improve GDM prediction, screening, and management. Nonetheless, broader validation, enhanced model interpretability, and prospective studies in diverse populations are needed to translate these technologies into clinical practice.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hypoglycemia and Glucagon

